CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Lopinavir 200Mg/Ritonavir 50Mg TabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug2422 TD-0903 Wiki 0.71
drug262 Azithromycin Wiki 0.17
drug1086 Hydroxychloroquine Wiki 0.10
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.21
D007249 Inflammation NIH 0.20
D055371 Acute Lung Injury NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization

COVID-19 is a respiratory disease due to a novel coronavirus (SARS-CoV-2) that causes substantial morbidity and mortality. To date, no treatment has been proved to be effective in COVID-19. Elderly patients and patients with comorbidities have the worse prognosis with a higher risk of hospitalization, ICU admission and death. The efficacy of an early outpatient treatment could be suggested but need to be confirmed. This confirmation is mandatory to improve prognosis of COVID-19 but also to avoid unsuspected deleterious effect of drugs already used in clinical practice but not based on evidence.

NCT04365582 COVID Drug: Azithromycin Drug: Hydroxychloroquine Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab

Primary Outcomes

Description: Hospitalization at D20

Measure: Hospital admission

Time: Day 20

Secondary Outcomes

Description: This outcome corresponds to the number of patients who died on day 20.

Measure: Effect of treatment on Death at D20

Time: Day 20

Description: This outcome corresponds to the number of patients who died on day 60.

Measure: Effect of treatment on Death at D60

Time: Day 60

Description: This outcome corresponds to the number of patients who died due to COVID on day 20.

Measure: Effect of treatment on Death due to COVID at D20

Time: Day 20

Description: This outcome corresponds to the number of patients who died due to COVID on day 60.

Measure: Effect of treatment on Death due to COVID at D60

Time: Day 60

Description: This outcome corresponds to the number of participants who need ICU stay at day 20.

Measure: Effect of treatment on need for ICU stay at D20

Time: Day 20

Description: This outcome corresponds to the number of participants who need ICU stay at day 60.

Measure: Effect of treatment on need for ICU stay at D60

Time: Day 60

Description: This outcome evaluates the duration of patient's ICU stay at day 20.

Measure: Effect of treatment on duration of ICU stay at D20

Time: Day 20

Description: This outcome evaluates the duration of patient's ICU stay at day 60.

Measure: Effect of treatment on duration of ICU stay at D60

Time: Day 60

Description: This outcome corresponds to the number of participants who need mechanical ventilation at D20.

Measure: Effect of treatment on need of mechanical ventilation at D20

Time: Day 20

Description: This outcome corresponds to the number of participants who need mechanical ventilation at D60.

Measure: Effect of treatment on need of mechanical ventilation at D60

Time: Day 60

Description: This outcome corresponds to the duration of patient's mechanical ventilation at D20.

Measure: Effect of treatment on duration of mechanical ventilation at D20

Time: Day 20

Description: This outcome corresponds to the duration of patient's mechanical ventilation at D60.

Measure: Effect of treatment on duration of mechanical ventilation at D60

Time: Day 60

Description: This outcome evaluates the delay between inclusion and hospitalization at D20.

Measure: Effect of treatment on time to hospitalization at D20

Time: Day 20

Description: This outcome evaluates the delay between inclusion and hospitalization at D60.

Measure: Effect of treatment on time to hospitalization at D60

Time: Day 60

Description: This outcome evaluates the duration of patient's Hospital stay at D20.

Measure: Effect of treatment on Duration of Hospital stay et D20

Time: Day 20

Description: This outcome evaluates the duration of patient's Hospital stay at D60.

Measure: Effect of treatment on Duration of Hospital stay et D60

Time: Day 60

Description: This outcome evaluates the duration of symptoms at D20 after treatment.

Measure: Effect of treatment on Duration of symptoms at D20

Time: Day 20

Description: This outcome evaluates the duration of symptoms at D60 after treatment.

Measure: Effect of treatment on Duration of symptoms at D60

Time: Day 60

Description: This outcome measures the number of participants with treatment-related adverse events as assessed by CTCAE v4.0, at the end of study.

Measure: Incidence of Treatment-Emergent Adverse Events

Time: Month 6

Other Outcomes

Description: This outcome evaluates the chest radiological features on Chest HRCT, at 6 months, after treatment.

Measure: Effect of treatment on chest radiological features

Time: Month 6

Description: This outcome evaluates the Pulmonary function test at 6 month, after treatment.

Measure: Effect of treatment on respiratory capacity

Time: Month 6

Description: This ouctome eavaluates costs and consequences which will be presented for each stakeholder in a disaggregated way at the end of study.

Measure: Cost consequence analysis

Time: Month 6


No related HPO nodes (Using clinical trials)